moatshark My

All holdings

Vaxcyte

PCVX

Source: the SEC Form 13F filings of the managers we follow, latest for Q3 2026. How we use them

Managers holding
0
In their latest 13F (Q3 2026)
See who
Value held
$0k
Combined value at quarter end
Last quarter
0 bought
1 sold or trimmed
Price at Q1 ’26 end
$58.11

Prices here are quarter-end prices implied by the 13F filings. Today’s price on Yahoo Finance

Managers holding it, by quarter

0Q4 ’23
0Q1 ’24
0Q2 ’24
0Q3 ’24
0Q4 ’24
0Q1 ’25
0Q2 ’25
0Q3 ’25
0Q4 ’25
1Q1 ’26
0Q2 ’26
0Q3 ’26
Q4 ’23: 0; Q1 ’24: 0; Q2 ’24: 0; Q3 ’24: 0; Q4 ’24: 0; Q1 ’25: 0; Q2 ’25: 0; Q3 ’25: 0; Q4 ’25: 0; Q1 ’26: 1; Q2 ’26: 0; Q3 ’26: 0

Counts the managers on this site whose 13F for that quarter includes Vaxcyte.

Who holds it

Each manager’s latest 13F, sorted by how much of their portfolio it is. Changes are against their previous quarter.

No manager on this site held it in their latest 13F.

Download the holders: CSV · JSON · Markdown

Directors buying and selling

Open-market trades by directors, officers and 10% holders over the last 12 months. How this works
From their Form 4 filings with the SEC. Grants, option exercises and shares sold to pay tax are left out.
Insider purchases and sales of Vaxcyte
Bought or soldFiling
5 Oct 2026Cowan ElviaSVP, Finance & CAO▼ Sold19,000$86.74$1.6mForm 4
5 Oct 2026Wassil JimEVP, Chief Scientific Ofc, COO▼ Sold18,000$86.74$1.6mForm 4
1 Oct 2026Wassil JimEVP, Chief Scientific Ofc, COO▼ Sold2,155$56.65$122kForm 4
1 Oct 2026Wassil JimEVP, Chief Scientific Ofc, COO▼ Sold95$57.09$5kForm 4
9 Sep 2026Wassil JimEVP, Chief Scientific Ofc, COO▼ Sold1,334$59.52$79kForm 4
4 Sep 2026Wassil JimEVP, Chief Scientific Ofc, COO▼ Sold1,381$61.16$84kForm 4
1 Sep 2026Wassil JimCHIEF OPERATING OFFICER▼ Sold1,537$60.89$94kForm 4
1 Sep 2026Wassil JimCHIEF OPERATING OFFICER▼ Sold924$60.95$56kForm 4
1 Sep 2026Wassil JimCHIEF OPERATING OFFICER▼ Sold713$61.48$44kForm 4
1 Sep 2026Wassil JimCHIEF OPERATING OFFICER▼ Sold303$61.42$19kForm 4
5 Aug 2026Dhaliwal Harpreet S.Chief Technical Ops Officer▼ Sold17,000$55.00$935kForm 4
3 Aug 2026Guggenhime AndrewPRESIDENT AND CFO▼ Sold6,956$53.76$374kForm 4
3 Aug 2026Guggenhime AndrewPRESIDENT AND CFO▼ Sold3,044$54.18$165kForm 4
3 Aug 2026Wassil JimCHIEF OPERATING OFFICER▼ Sold1,389$54.09$75kForm 4
3 Aug 2026Wassil JimCHIEF OPERATING OFFICER▼ Sold861$53.50$46kForm 4
27 Jul 2026Pickering GrantCHIEF EXECUTIVE OFFICER▼ Sold11,783$55.52$654kForm 4
27 Jul 2026Pickering GrantCHIEF EXECUTIVE OFFICER▼ Sold4,415$55.93$247kForm 4
27 Jul 2026Pickering GrantCHIEF EXECUTIVE OFFICER▼ Sold756$55.52$42kForm 4
27 Jul 2026Pickering GrantCHIEF EXECUTIVE OFFICER▼ Sold622$55.54$35kForm 4
27 Jul 2026Pickering GrantCHIEF EXECUTIVE OFFICER▼ Sold378$55.91$21kForm 4

About the company

Sector
Health care · Biological Products, (No Diagnostic Substances)
Incorporated in
Delaware
Financial year ends
31 December
Shares outstanding
149m at 3 Aug 2026
SEC filings
Annual reports and other filings on EDGAR

Revenue and profit

Vaxcyte revenue and net income by year
YearRevenueNet income
2025–−$767k
2024–−$464k
2023–−$402k
2022–−$223k
2021–−$100k
2020–−$89.2m
2019–−$50.3m
2018–−$29.5m

From the company’s XBRL financial statements filed with the SEC, for each financial year. Gaps mean the company didn’t report that figure in a standard form.

Sold out last quarter